Fludrocortisone Acetate Tablets (Aspen) (50455) [Archived]
Fludrocortisone Acetate Tablets (Aspen) (50455) [Archived]

The following Competition practice note provides comprehensive and up to date legal information covering:

  • Fludrocortisone Acetate Tablets (Aspen) (50455) [Archived]
  • Case facts
  • Timeline
  • Commentary
  • Related cases

CASE HUB

ARCHIVED–this archived case hub reflects the position at the date of the decision of 9 July 2020; it is no longer maintained.

See further, timeline, commentary andrelated cases

Case facts

OutlineCMA Article 101 TFEU/Chapter I and Article 102 TFEU/Chapter II investigation into Aspen’s alleged breach of competition law in relation to the supply of fludrocortisone acetate tablets in the UK.

Latest developmentsOn 9 July 2020, the CMA issued its infringement decision, finding that Aspen unlawfully agreed to pay two other firms, Amilco and Tiofarma, to stay out of the UK market for fludrocortisone acetate tablets so that Aspen could maintain its position as the sole UK supplier of fludrocortisone, allowing it to raise prices by 1,800%. The CMA imposed a fine totalling £2.3. In addition, Aspen has made a payment of £8m to the NHS.

Parties• Aspen Pharmacare Holdings Ltd, Aspen Global Inc., Apsen Pharma Ireland Ltd, and Aspen Pharma Trading Ltd (together, Aspen: Aspen is a multinational pharmaceutical group with its headquarters in South Africa. It owns a broad portfolio of branded and generic prescription products that are sold to wholesalers, hospitals and pharmacies in over 100 countries.

• Amilco Limited (Amilco): Amilco is a UK based company that specialise in the sale of medical stock.

• Tiofarma and Tiofarma Beheer (together, Tiofa

Popular documents